TREATMENT OF THE MALIGNANT CARCINOID-SYNDROME - EVALUATION OF A LONG-ACTING SOMATOSTATIN ANALOG
TREATMENT OF THE MALIGNANT CARCINOID-SYNDROME - EVALUATION OF A LONG-ACTING SOMATOSTATIN ANALOG
复制标题
DOI：
10.1056/nejm198609113151102
复制
发表时间：
1986-09-11
影响因子：
158.5
通讯作者：
HAHN, RG
中科院分区：
文献类型：
--
作者：
KVOLS, LK;MOERTEL, CG;HAHN, RG
我们研究了生长抑素的长效类似物（SMS 201-995，山德士）在25例经组织学证实的转移性类癌肿瘤和类癌综合征患者中的作用。该药物通过皮下注射以150 μ g的剂量每日三次自我给药。22例患者的潮红和腹泻症状迅速缓解。所有25例患者的24小时尿5-羟基吲哚乙酸（5-HIAA）排泄量均升高（平均值为265 mg/24小时;范围为14 - 1079），这是疾病活动的客观指标。与治疗前的值相比，25名患者中的18名（72%）的尿5-HIAA水平下降了50%或更多。这种生化反应的中位持续时间超过12个月（范围，1至> 18）。由于没有观察到严重的毒性，我们得出结论，SMS 201-995可能适用于早期治疗的症状，由于类癌综合征谁没有回应简单的措施。
We studied the effects of a long-acting analogue of somatostatin (SMS 201-995, Sandoz) in 25 patients with histologically proved metastatic carcinoid tumors and the carcinoid syndrome. This drug was self-administered by subcutaneous injection at a dose of 150 .mu.g three times daily. Flushing and diarrhea associated with the syndrome were promptly relieved in 22 patients. All 25 patients had an elevated 24-hour urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) (mean, 265 mg per 24 hours; range, 14 to 1079), which served as an objective indicator of disease activity. Eighteen of the 25 patients (72 percent) had a decrease of 50 percent or more in their urinary 5-HIAA levels, as compared with the pretreatment values. The median duration of this biochemical response was more than 12 months (range, 1 to > 18). Since no serious toxicity was observed, we conclude that SMS 201-995 may be appropriate for use as early therapy in patients with symptoms due to the carcinoid syndrome who have not responded to simpler measures.